Fusion Antibodies PLC Director/PDMR Shareholding (4080E)
03 Julio 2019 - 10:09AM
UK Regulatory
TIDMFAB
RNS Number : 4080E
Fusion Antibodies PLC
03 July 2019
03 July 2019
Fusion Antibodies plc
("Fusion" or the "Company")
Director/PDMR Shareholding
Fusion Antibodies plc (AIM: FAB), a contract research
organisation providing a range of antibody engineering services for
the development of antibodies for both therapeutic drug and
diagnostic applications, announces the following purchases of
ordinary shares in the Company ("Ordinary Shares") by certain
directors.
On 02 July 2019, Dr Paul Kerr, Chief Executive Officer,
purchased 6,920 Ordinary Shares at a price of 72.896 pence per
Ordinary Share. Following this purchase, Paul Kerr has a direct and
indirect interest in 540,710 Ordinary Shares, representing
approximately 2.45 per cent. of the Company's issued share
capital.
On 02 July 2019, Alan Mawson, Non-Executive Director, purchased
10,000 Ordinary Shares into his pension fund at a price of 59 pence
per Ordinary Share. Following this purchase, Alan Mawson has a
direct and indirect interest in 53,988 Ordinary Shares,
representing approximately 0.24 per cent. of the Company's issued
share capital. Alan Mawson is also a Non-Executive Director of
Clarendon Fund Managers Limited ("Clarendon") and sits on
Clarendon's investment committee. Clarendon is the fund manager for
Nitech Growth Fund LP which holds 358,850 Ordinary Shares and
Viridian Growth Fund LP which holds 1,831,500 Ordinary Shares.
On 02 July 2019, Sonya Ferguson, Non-Executive Director,
purchased 30,000 Ordinary Shares at a price of 69.5 pence per
Ordinary Share. Following this purchase, Sonya Ferguson has a
direct and indirect interest in 60,900 Ordinary Shares,
representing approximately 0.28 per cent. of the Company's issued
share capital.
The following notifications, made in accordance with the
requirements of the EU Market Abuse Regulation, give further
details.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Paul Kerr
------------------------- ------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Fusion Antibodies plc
------------------------- ------------------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary shares of 4p each in Fusion Antibodies
the financial plc
instrument, type Identification code (ISIN) for Fusion
of instrument Antibodies plc ordinary shares:
Identification GB00BDQZGK16
code
------------------------- ------------------------------------------------
b) Nature of the Purchase of shares
transaction
------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
72.896p 6,920
----------
------------------------- ------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------- ------------------------------------------------
e) Date of the transaction 02 July 2019
------------------------- ------------------------------------------------
f) Place of the transaction London Stock Exchange, XLON
------------------------- ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Alan Mawson
------------------------- ------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Fusion Antibodies plc
------------------------- ------------------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary shares of 4p each in Fusion Antibodies
the financial plc
instrument, type Identification code (ISIN) for Fusion
of instrument Antibodies plc ordinary shares:
Identification GB00BDQZGK16
code
------------------------- ------------------------------------------------
b) Nature of the Purchase of shares
transaction
------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
59p 10,000
----------
------------------------- ------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------- ------------------------------------------------
e) Date of the transaction 02 July 2019
------------------------- ------------------------------------------------
f) Place of the transaction London Stock Exchange, XLON
------------------------- ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sonya Ferguson
------------------------- ------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Fusion Antibodies plc
------------------------- ------------------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary shares of 4p each in Fusion Antibodies
the financial plc
instrument, type Identification code (ISIN) for Fusion
of instrument Antibodies plc ordinary shares:
Identification GB00BDQZGK16
code
------------------------- ------------------------------------------------
b) Nature of the Purchase of shares
transaction
------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
69.5p 30,000
----------
------------------------- ------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------- ------------------------------------------------
e) Date of the transaction 02 July 2019
------------------------- ------------------------------------------------
f) Place of the transaction London Stock Exchange, XLON
------------------------- ------------------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Via Walbrook PR
Officer
James Fair, Chief Financial
Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Anna Dunphy Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx(TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced over 250 antibodies and successfully completed over 100
humanisation projects for its international, blue-chip client base,
which includes eight of the top 10 global pharmaceutical companies
by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. It was initially a drug development business
but revised its operations to focus on CRO work in 2011. The
Company has a highly experienced management team with a combined 47
years' experience in the biopharma industry.
The global monoclonal antibody therapeutics market, which
accounted for 43 per cent. of the global biologics market in 2016,
was valued at between $85.4 billion and $86.7 billion in 2015 and
is forecast to increase at a CAGR of between 8.2 per cent. and 12.2
per cent. for the period 2016 to 2024.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSSIFIDFUSESW
(END) Dow Jones Newswires
July 03, 2019 11:09 ET (15:09 GMT)
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
